Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment

Reuters02-12 10:03

Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment

Teijin Pharma Limited has applied for manufacturing and marketing approval in Japan for lonapegsomatropin, a once-weekly treatment for pediatric growth hormone deficiency (GHD). The application, submitted to the Pharmaceuticals and Medical Devices Agency on February 12, 2026, is based on global Phase III clinical trial results conducted by Ascendis Pharma. Lonapegsomatropin, developed as TransCon hGH by Ascendis Pharma, delivers unmodified somatropin and has demonstrated superiority in annualized height velocity compared to daily somatropin, with a similar safety profile. Teijin Pharma Limited holds exclusive rights to the treatment in Japan through a licensing agreement with Ascendis Pharma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610996943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610996943","market":"us","top_or_hot":-1,"title":"Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teijin Pharma Limited has applied for manufacturing and marketing approval in Japan for lonapegsomatropin, a once-weekly treatment for pediatric growth hormone deficiency (GHD). The application, submitted to the Pharmaceuticals and Medical Devices Agency on February 12, 2026, is based on global Phase III clinical trial results conducted by Ascendis Pharma. Lonapegsomatropin, developed as TransCon hGH by Ascendis Pharma, delivers unmodified somatropin and has demonstrated superiority in annualized height velocity compared to daily somatropin, with a similar safety profile. Teijin Pharma Limited holds exclusive rights to the treatment in Japan through a licensing agreement with Ascendis Pharma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teijin Pharma Limited has applied for manufacturing and marketing approval in Japan for lonapegsomatropin, a once-weekly treatment for pediatric growth hormone deficiency (GHD). The application, submitted to the Pharmaceuticals and Medical Devices Agency on February 12, 2026, is based on global Phase III clinical trial results conducted by Ascendis Pharma. Lonapegsomatropin, developed as TransCon hGH by Ascendis Pharma, delivers unmodified somatropin and has demonstrated superiority in annualized height velocity compared to daily somatropin, with a similar safety profile. Teijin Pharma Limited holds exclusive rights to the treatment in Japan through a licensing agreement with Ascendis Pharma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL3hTwy9:1","article_id":"2610996943","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610996943","pubTimestamp":1770861784,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Teijin Pharma Limited has applied for manufacturing and marketing approval in Japan for lonapegsomatropin, a once-weekly treatment for pediatric growth hormone deficiency . The application, submitted to the Pharmaceuticals and Medical Devices Agency on February 12, 2026, is based on global Phase III clinical trial results conducted by Ascendis Pharma. Lonapegsomatropin, developed as TransCon hGH by Ascendis Pharma, delivers unmodified somatropin and has demonstrated superiority in annualized height velocity compared to daily somatropin, with a similar safety profile. Teijin Pharma Limited holds exclusive rights to the treatment in Japan through a licensing agreement with Ascendis Pharma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","BK":"纽约梅隆银行","BK4139":"生物科技","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4559":"巴菲特持仓","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4135":"资产管理与托管银行","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"帝人制药申请日本批准每周一次的儿科生长激素治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BK":0.9,"ASND":0.9},"content_text":"Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment\n    \n\n        Teijin Pharma Limited has applied for manufacturing and marketing approval in Japan for lonapegsomatropin, a once-weekly treatment for pediatric growth hormone deficiency (GHD). The application, submitted to the Pharmaceuticals and Medical Devices Agency on February 12, 2026, is based on global Phase III clinical trial results conducted by Ascendis Pharma. Lonapegsomatropin, developed as TransCon hGH by Ascendis Pharma, delivers unmodified somatropin and has demonstrated superiority in annualized height velocity compared to daily somatropin, with a similar safety profile. Teijin Pharma Limited holds exclusive rights to the treatment in Japan through a licensing agreement with Ascendis Pharma.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610996943","isCrawlerRequest":true}